Abstract
NADH/FAD fluorescence spectroscopy/imaging is an extremely useful tool to probe cellular metabolism and has been applied in the clinic such as early cancer detection. Recently, the potential of using NADH/FAD fluorescence as a biomarker to detect cell death has been investigated for development of cancer treatments with higher efficacy. This review aims to provide the updated information in cell death detection using the NADH/FAD fluorescence spectroscopy and imaging based on measurement of the intensity or lifetime of NADH or FAD fluorescence. The response of NADH fluorescence lifetime to metabolic perturbation, hypoxic environment, and anaerobic glycolysis (e.g., in precancerous tissues and stem cells) is also reviewed to discuss the nature and implications of the lifetime change of NADH fluorescence. Further studies are required to understand the actual site and mechanism of NADH binding of a specific death pathway for future successful in vivo detection of cell death using the NADH fluorescence lifetime.
Keywords: NAD(P)H and FAD fluorescence intensity and lifetime, redox ratio, mitochondrial respiration, cell death
Anti-Cancer Agents in Medicinal Chemistry
Title: Reduced Nicotinamide Adenine Dinucleotide (NADH) Fluorescence for the Detection of Cell Death
Volume: 9 Issue: 9
Author(s): Hsing-Wen Wang, Yau-Huei Wei and Han-Wen Guo
Affiliation:
Keywords: NAD(P)H and FAD fluorescence intensity and lifetime, redox ratio, mitochondrial respiration, cell death
Abstract: NADH/FAD fluorescence spectroscopy/imaging is an extremely useful tool to probe cellular metabolism and has been applied in the clinic such as early cancer detection. Recently, the potential of using NADH/FAD fluorescence as a biomarker to detect cell death has been investigated for development of cancer treatments with higher efficacy. This review aims to provide the updated information in cell death detection using the NADH/FAD fluorescence spectroscopy and imaging based on measurement of the intensity or lifetime of NADH or FAD fluorescence. The response of NADH fluorescence lifetime to metabolic perturbation, hypoxic environment, and anaerobic glycolysis (e.g., in precancerous tissues and stem cells) is also reviewed to discuss the nature and implications of the lifetime change of NADH fluorescence. Further studies are required to understand the actual site and mechanism of NADH binding of a specific death pathway for future successful in vivo detection of cell death using the NADH fluorescence lifetime.
Export Options
About this article
Cite this article as:
Wang Hsing-Wen, Wei Yau-Huei and Guo Han-Wen, Reduced Nicotinamide Adenine Dinucleotide (NADH) Fluorescence for the Detection of Cell Death, Anti-Cancer Agents in Medicinal Chemistry 2009; 9 (9) . https://dx.doi.org/10.2174/187152009789377718
DOI https://dx.doi.org/10.2174/187152009789377718 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Novel Patents Targeting Interleukin-17A; Implications in Cancer and Inflammation
Recent Patents on Anti-Cancer Drug Discovery The Yin and Yang of microRNA Assay Methods
MicroRNA Autoimmunity and Frontotemporal Dementia
Current Alzheimer Research Nanomedicines Based Drug Delivery Systems for Anti-Cancer Targeting and Treatment
Current Drug Delivery Exosomal microRNAs as Potentially Useful Tools in Cancer Biomarker Discovery
Recent Patents on Biomarkers Melatonin and Synthetic Melatoninergic Agonists in Psychiatric and Age-associated Disorders: Successful and Unsuccessful Approaches
Current Pharmaceutical Design Left-Right Asymmetry in Embryonic Development and Breast Cancer: Common Molecular Determinants?
Current Medicinal Chemistry High Order Texture-Based Analysis in Biomedical Images
Current Medical Imaging Platinum Formulations as Anticancer Drugs Clinical and Pre-Clinical Studies
Current Topics in Medicinal Chemistry Nasal Polyposis: An Overview of Differential Diagnosis and Treatment
Recent Patents on Inflammation & Allergy Drug Discovery The Interest of Folic Acid in Targeted Photodynamic Therapy
Current Medicinal Chemistry Interfering with Hedgehog Pathway: New Avenues for Targeted Therapy in Rhabdomyosarcoma
Current Drug Targets Nucleic Acid-Based Therapeutics for Glioblastoma
Anti-Cancer Agents in Medicinal Chemistry miR-629-3p Level Significantly Predicts Prognosis in Glioblastoma Patients Treated with Temozolomide Chemotherapy
Current Signal Transduction Therapy Attention Deficit Hyperactivity Disorder and N-methyl-D-aspartate (NMDA) Dysregulation
Current Pharmaceutical Design Oncolytic Herpes Simplex Virus Type 1 and Host Immune Responses
Current Cancer Drug Targets Convection Enhanced Delivery of Macromolecules for Brain Tumors
Current Drug Discovery Technologies Nanomedical Applications of Amphiphilic Dendrimeric Micelles
Current Medicinal Chemistry New Therapeutic Strategies for Cancer and Neurodegeneration Emerging from Yeast Cell-based Systems
Current Pharmaceutical Design STAT3 as a Central Regulator of Tumor Metastases
Current Molecular Medicine